Preventing major operative site infection after radical abdominal hysterectomy and pelvic lymphadenectomy

David L. Hemsell, Steven G. Bernstein, Roger E. Bawdon, Patricia G. Hemsell, Molly C. Heard, Brenda J. Nobles

Research output: Contribution to journalArticlepeer-review

15 Scopus citations


Twenty-one women who underwent radical abdominal hysterectomy and pelvic lymphadenectomy were enrolled in a prospective, comparative, randomized, placebo-controlled clinical trial of antimicrobial prophylaxis. Preoperative endocervical flora was identified and was similar in pre- and postmenopausal private and clinic service women; 46% of the 119 preoperative isolates produced β-lactamase enzyme. Women were given three doses of either placebo or cefoperazone plus sulbactam, an irreversible β-lactamase enzyme inhibitor. Three women (27%) given placebo developed abdominal incision infections; one woman given placebo also developed a pelvic infection. None given antibiotic developed operative site infection, but one woman developed a drain site infection. A major operative site infection rate of 27% observed with placebo is high enough to warrant prophylaxis. Although antimicrobial prophylaxis at radical hysterectomy and pelvic lymphadenectomy eradicted operative site infection in our patient populations, a literature review indicates that individual determination of a requirement for prophylaxis is necessary.

Original languageEnglish (US)
Pages (from-to)55-60
Number of pages6
JournalGynecologic oncology
Issue number1
StatePublished - Oct 1989

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynecology


Dive into the research topics of 'Preventing major operative site infection after radical abdominal hysterectomy and pelvic lymphadenectomy'. Together they form a unique fingerprint.

Cite this